Groupe Bruxelles Lambert S.A.
GBLBF
Other OTC93.94
USD
-1.06
- -
Groupe Bruxelles Lambert S.A.
GBLBF
(Other OTC)
Recent
price
93.94
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Groupe Bruxelles Lambert S.A. (GBL) is a Belgian investment holding company primarily engaged in managing a diversified portfolio of industrial and financial assets with a strategic long-term value creation focus. Founded in 1956 and headquartered in Brussels, Belgium, GBL operates through significant stakes in listed and private companies across several sectors including consumer goods, materials, healthcare, and services. Its core investments encompass equity stakes in globally leading companies such as SGS (inspection, audit, and certification services); Pernod Ricard (spirits production); adidas and Canyon (sporting goods manufacturing and sales); Imerys (specialty materials extraction and production); Umicore (automotive catalysts and battery materials); Affidea and Sanoptis (pan-European healthcare diagnostics and outpatient services); and several private equity holdings through its GBL Capital arm. GBL’s main products and services include equity investment and active portfolio management focusing on value creation in sectors such as consumer goods, industrial materials, healthcare, and private equity-backed services. The company provides capital, strategic guidance, and operational expertise to its portfolio companies. Its geographic reach is primarily European but with global exposure through holdings in multinational corporations. Recent major company changes include the strategic acquisition of a 5% equity stake in Sagard, a global alternative asset management firm, through its subsidiary GBL Capital in early 2025, enhancing its private equity investment capabilities and committing significant capital over the coming years to Sagard-managed strategies. GBL also completed several acquisitions to strengthen its healthcare platforms, notably Affidea and Sanoptis, including Sanoptis’ €250 million capital raise in partnership with Carlyle to accelerate growth and expansion initiatives. Operationally, GBL continues to crystallize value from disposals in its listed asset portfolio, including moves related to SGS, and rebalances its portfolio towards direct private asset exposure. The company reported robust financial performance with a 2024 portfolio value of approximately €14 billion and maintains a strong liquidity position to capitalize on investment opportunities. GBL focuses on sustainable investment principles, emphasizing Environmental, Social, and Governance (ESG) criteria, with objectives to reduce greenhouse gas emissions and enhance long-term shareholder value. Its investment approach leverages strategic partnerships, disciplined capital allocation, and active management to support innovation and growth across its portfolio. The company is controlled by the Frère family and institutional investors, reflecting a stable shareholder base aligned with its long-term investment vision.
CVC, Groupe Bruxelles Lambert Make $12.5 Billion Bid to Take Recordati Private
Umicore - Transparency notification by Groupe Bruxelles Lambert S.A.
Groupe Bruxelles: A Big 2025 Winner I Called And Missed
Groupe Bruxelles Lambert: The Ultimate Turnaround Play